What is Guardant Health Inc (GH) stock price today?

Guardant Health Inc (GH) currently trades at $83.41 per share. The stock has a market capitalization of $11.06B and a P/E ratio of —x.

Is GH stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Guardant Health Inc has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -2.02.

What is Guardant Health Inc's revenue and earnings?

Guardant Health Inc has trailing twelve-month (TTM) revenue of $982.02M with profit margins of -42.40%. Earnings per share (EPS) is $-3.32.

Is Guardant Health Inc financially healthy?

Guardant Health Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -2.02 places it in the distress.

Guardant Health Inc

NASDAQ: GH · HEALTHCARE · DIAGNOSTICS & RESEARCH

$83.41

+0.39% today

Updated 2026-04-29

Market cap

$11.06B

P/E ratio

—

P/S ratio

11.26x

EPS (TTM)

$-3.32

Dividend yield

—

52W range

$36 – $121

Volume

2.0M

Market cap

$11.06B

P/E ratio

—

P/S ratio

11.26x

EPS (TTM)

$-3.32

Dividend yield

—

52W range

$36 – $121

Volume

2.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

6.5

Quality

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-2.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$128.33

+53.85%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

5 Strong Buy16 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 39.40% QoQ

+ Debt/equity -3.74x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -2.02 — distress zone

- Thin margins at -42.40%

- Negative free cash flow $-41.93M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$449.54M	$563.95M	$739.02M	$982.02M	$982.02M
Net income	$-654.59M	$-479.45M	$-436.37M	$-416.28M	$-128.49M
EPS	—	—	—	—	$-3.32
Free cash flow	$-386.92M	$-345.46M	$-274.94M	$-233.07M	$-41.93M
Profit margin	-145.61%	-85.02%	-59.05%	-42.39%	-42.40%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-21	MIGNONE, ROBERTO	Sale	264	—
2026-04-21	MIGNONE, ROBERTO	Buy	264	—
2026-04-17	HIDALGO, MEDINA MANUEL	Sale	232	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GH	$11.06B	31	8.0	2.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Guardant Health Inc trades at $83.41. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -2.02, it sits in the distress. TTM revenue stands at $982.02M. with profit margins at -42.40%.

Frequently asked questions

What is Guardant Health Inc's stock price?

Guardant Health Inc (GH) trades at $83.41.

Is Guardant Health Inc overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Guardant Health Inc (GH)?

The analyst target price is $128.33, representing +53.9% upside from the current price of $83.41.

What is Guardant Health Inc's revenue?

TTM revenue is $982.02M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-2.02 — distress.

Company info

SectorHEALTHCARE

IndustryDIAGNOSTICS & RESEARCH

CountryUSA

ExchangeNASDAQ

CurrencyUSD

guardanthealth.com

Quick metrics

P/S ratio11.26x

ROE-4,584.00%

Beta1.65

50D MA$89.96

200D MA$83.18

Shares out0.13B

Float0.13B

Short ratio—

Avg volume2.0M

Performance

1 week-7.22%

1 month-3.61%

3 months-24.28%

YTD-18.65%

1 year—

3 years—

5 years—

Compare

GH vs LLY →GH vs JNJ →GH vs ABBV →Stock screener →